Cost-effectiveness of immediate HCV Rx in early disease analyzed

Cost-effectiveness of immediate HCV rx in early disease analyzed

(HealthDay)—For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in Hepatology.

Andrew J. Leidner, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined the cost-effectiveness of new treatments for HCV, with a focus on patients in the early stages of liver disease. A state-transition model was developed to calculate costs incurred and quality-adjusted life-years (QALYs) gained by following HCV . Incremental cost-effectiveness ratios for treatment were computed at different stages of liver disease versus delaying treatment until the subsequent stage. Potential benefits linked to reduced non-liver-related mortality or preventing HCV transmission were not included in analyses.

The researchers found that the best case scenario represented a patient aged 55 years with HCV genotype 1 infection for whom the treatment cost was $100,000 and treatment effectiveness was 90 percent. The cost-effectiveness of immediately initiating treatment at Metavir stage F2 (moderate ) versus delaying treatment until F3 was $37,300 per QALY. The threshold of treatment costs that yielded cost-effectiveness ratios of $50,000/QALY and $100,000/QALY were $22,200 and $42,400, respectively, for patients immediately treated at F0 versus delaying treatment until F1.

"Immediate treatment of HCV-infected patients with moderate and advanced fibrosis appears to be cost-effective," the authors write. "Immediate treatment of with minimal or no fibrosis can be cost-effective as well, particularly when lower treatment costs are assumed."

The study was partially funded by pharmaceutical companies.

Explore further

Cerebrovascular reserve-based strategy is cost-effective

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Hepatology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Cost-effectiveness of immediate HCV Rx in early disease analyzed (2015, February 18) retrieved 20 January 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors